Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 201–300 of 1,014
An, J., Wang, C., Deng, Y., Yu, L., & Huang, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.013 · Cited by 260
Cancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
Self-citationThe cancer genome atlas pan-cancer analysis project
Mills, G. B., Mills Shaw, K. R., Shmulevich, I., Stuart, J. M., Ellrott, K., Sander, C., The Cancer Genome Atlas Research Network, Collisson, E. A., Ozenberger, B. A., & Weinstein, J. N. (2019) · PubMed · doi:10.17615/670y-yr53 · Cited by 261
Nam, R. K., Sugar, L., Yang, W., Srivastava, S., Klotz, L. H., Yang, L.-Y., Stanimirovic, A., Encioiu, E., Neill, M., Loblaw, D. A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604054 · Cited by 257
Kumar, A., White, T. A., MacKenzie, A. P., Clegg, N., Lee, C., Dumpit, R. F., Coleman, I., Ng, S. B., Salipante, S. J., Rieder, M. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108745108 · Cited by 263
Self-citationAndrogen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer
Dehm, S. M., & Tindall, D. J. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0223 · Cited by 253
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Massie, C. E., Adryan, B., Barbosa‐Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., & Mills, I. G. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401046 · Cited by 259
Beyond DNA Repair: DNA-PK Function in Cancer
Goodwin, J. F., & Knudsen, K. E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0358 · Cited by 258
Sun, C., Dobi, A., Mohamed, A., Li, H., Thangapazham, R. L., Furusato, B., Shaheduzzaman, S., Tan, S.-H., Vaidyanathan, G., Whitman, E., et al. (2008) · Oncogene · doi:10.1038/onc.2008.183 · Cited by 253
Mosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., Perner, S., Bismar, T. A., Erbersdobler, A., Dhir, R., et al. (2013) · Neoplasia · doi:10.1593/neo.121550 · Cited by 249
Self-citationTMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
Gopalan, A., Leversha, M. A., Satagopan, J. M., Zhou, Q., Al-Ahmadie, H. A., Fine, S. W., Eastham, J. A., Scardino, P. T., Scher, H. I., Tickoo, S. K., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2467 · Cited by 246
Big data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254
ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors
Oh, S., Shin, S., & Janknecht, R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.02.002 · Cited by 249
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Minner, S., Enodien, M., Sirma, H., Luebke, A. M., Krohn, A., Mayer, P. S., Simon, R., Tennstedt, P., Müller, J., Scholz, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1251 · Cited by 249
on behalf of the Transatlantic Prostate Group, Reid, A. H. M., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605554 · Cited by 250
TMPRSS2 : ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis
Saramäki, O. R., Harjula, A. E., Martikainen, P. M., Vessella, R. L., Tammela, T. L. J., & Visakorpi, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2051 · Cited by 243
Iljin, K., Wolf, M., Edgren, H., Gupta, S., Kilpinen, S., Skotheim, R. I., Peltola, M., Smit, F., Verhaegh, G., Schalken, J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1986 · Cited by 241
DNA Repair in Prostate Cancer: Biology and Clinical Implications
Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P. S., Olmos, D., Pritchard, C. C., Rubin, M. A., & de Bono, J. S. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.037 · Cited by 239
Self-citationEML4-ALK Fusion Lung Cancer: A Rare Acquired Event
Perner, S., Wagner, P. L., Demichelis, F., Mehra, R., LaFargue, C. J., Moss, B. J., Arbogast, S., Soltermann, A., Weder, W., Giordano, T. J., et al. (2008) · Neoplasia · doi:10.1593/neo.07878 · Cited by 249
Self-citationHermans, K. G., van Marion, R., van Dekken, H., Jenster, G., van Weerden, W. M., & Trapman, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1871 · Cited by 240
“Subsequently, it was shown that overexpression of ERG and related ETV1 was due to fusion of the TMPRSS2 gene to either ERG or ETV1 ( 3 ).”
BackgroundResultIljin, K., Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V., Grafström, R. C., Perälä, M., & Kallioniemi, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1035 · Cited by 240
The use of PCA3 in the diagnosis of prostate cancer
Hessels, D., & Schalken, J. A. (2009) · Nature Reviews Urology · doi:10.1038/nrurol.2009.40 · Cited by 239
Current treatment strategies for advanced prostate cancer
Komura, K., Sweeney, C. J., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. W. (2018) · International Journal of Urology · doi:10.1111/iju.13512 · Cited by 239
The Mutational Landscape of Prostate Cancer
Barbieri, C. E., Bangma, C. H., Bjartell, A., Catto, J. W. F., Culig, Z., Grönberg, H., Luo, J., Visakorpi, T., & Rubin, M. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.029 · Cited by 239
Self-citationCirculating Tumor Cells as Biomarkers in Prostate Cancer
Danila, D. C., Fleisher, M., & Scher, H. I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2650 · Cited by 244
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
“Tomlins et al. report that 40%–70% of prostate cancers have a chromosomal rearrangement that results in hormonal regulation of oncogenic ETS gene expression (Tomlins et al., 2005).”
BackgroundInfluentialAndrogen receptor and androgen-dependent gene expression in lung
Mikkonen, L., Pihlajamaa, P., Sahu, B., Zhang, F.-P., & Jänne, O. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.12.022 · Cited by 243
“These genes include TMPRSS2 (up-regulated by androgens in prostate cancer, Tomlins et al., 2005; Wang et al., 2007) and EPB41L4B (Bolton et al., 2007).”
BackgroundNoninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer
Laxman, B., Tomlins, S. A., Mehra, R., Morris, D. S., Wang, L., Helgeson, B. E., Shah, R. B., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2006) · Neoplasia · doi:10.1593/neo.06625 · Cited by 239
Self-citationProstate carcinogenesis: inflammatory storms
de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., & Alimonti, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0267-9 · Cited by 227
Ittmann, M., Huang, J., Radaelli, E., Martin, P., Signoretti, S., Sullivan, R., Simons, B. W., Ward, J. M., Robinson, B. D., Chu, G. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4213 · Cited by 232
TumorFusions: an integrative resource for cancer-associated transcript fusions
Hu, X., Wang, Q., Tang, M., Barthel, F., Amin, S., Yoshihara, K., Lang, F. M., Martinez-Ledesma, E., Lee, S. H., Zheng, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1018 · Cited by 238
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis
Wu, J. B., Shao, C., Li, X., Li, Q., Hu, P., Shi, C., Li, Y., Chen, Y.-T., Yin, F., Liao, C.-P., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70982 · Cited by 230
Furusato, B., Tan, S.-H., Young, D., Dobi, A., Sun, C., Mohamed, A. A., Thangapazham, R., Chen, Y., McMaster, G., Sreenath, T., et al. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.23 · Cited by 236
Mosquera, J.-M., Mehra, R., Regan, M. M., Perner, S., Genega, E. M., Bueti, G., Shah, R. B., Gaston, S., Tomlins, S. A., Wei, J. T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2927 · Cited by 234
Self-citationThe crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 224
Ernst, C., Deleva, V., Deng, X., Sequeira, A., Pomarenski, A., Klempan, T., Ernst, N., Quirion, R., Gratton, A., Szyf, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archpsyc.66.1.22 · Cited by 235
Genomic and Epigenomic Alterations in Cancer
Chakravarthi, B. V. S. K., Nepal, S., & Varambally, S. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.023 · Cited by 223
Self-citationClinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 229
Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer
Mano, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00972.x · Cited by 229
Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript
Benelli, M., Pescucci, C., Marseglia, G., Severgnini, M., Torricelli, F., & Magi, A. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts617 · Cited by 226
Epigenetics in Prostate Cancer: Biologic and Clinical Relevance
Jerónimo, C., Bastian, P. J., Bjartell, A., Carbone, G. M., Catto, J. W. F., Clark, S. J., Henrique, R., Nelson, W. G., & Shariat, S. F. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.035 · Cited by 226
“These ETS fusion genes are key to prostate carcinogenesis and involve the fusion of an androgenresponsive gene, androgen-regulated transmembrane protease, serine 2 (TMPRSS2) to members of the oncogenic ETS family, either ETS-related gene (ERG) or ETS variant gene 1 (ETV1) [108].”
BackgroundChallenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Beltran, H., Tagawa, S. T., Park, K., MacDonald, T., Milowsky, M. I., Mosquera, J. M., Rubin, M. A., & Nanus, D. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5166 · Cited by 229
Self-citationKobayashi, Y., Absher, D. M., Gulzar, Z. G., Young, S. R., McKenney, J. K., Peehl, D. M., Brooks, J. D., Myers, R. M., & Sherlock, G. (2011) · Genome Research · doi:10.1101/gr.119487.110 · Cited by 228
“…and gene fusions often involving the ETS family of transcription factors detectable in approximately half of prostate tumors (Singh et al. 2002; Lapointe et al. 2004; Tomlins et al. 2005, 2008; King et al. 2009; Sboner et al. 2010; Taylor et al. 2010; Pflueger et al. 2011; Robbins et al. 2011).”
Chromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Han, B., Mehra, R., Lonigro, R. J., Wang, L., Suleman, K., Menon, A., Palanisamy, N., Tomlins, S. A., Chinnaiyan, A. M., & Shah, R. B. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.69 · Cited by 227
Self-citationEvolution of the Androgen Receptor Pathway during Progression of Prostate Cancer
Hendriksen, P. J. M., Dits, N. F. J., Kokame, K., Veldhoven, A., van Weerden, W. M., Bangma, C. H., Trapman, J., & Jenster, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3082 · Cited by 226
Shi, T., Fillmore, T. L., Sun, X., Zhao, R., Schepmoes, A. A., Hossain, M., Xie, F., Wu, S., Kim, J.-S., Jones, N., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204366109 · Cited by 224
Self-citationSalami, S. S., Schmidt, F., Laxman, B., Regan, M. M., Rickman, D. S., Scherr, D., Bueti, G., Siddiqui, J., Tomlins, S. A., Wei, J. T., et al. (2013) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.04.001 · Cited by 221
Self-citationOu, S.-H. I., Bartlett, C. H., Mino-Kenudson, M., Cui, J., & Iafrate, A. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0311 · Cited by 224
Complexities of Prostate Cancer
Wasim, S., Lee, S.-Y., & Kim, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214257 · Cited by 191
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Ozawa, T., Brennan, C. W., Wang, L., Squatrito, M., Sasayama, T., Nakada, M., Huse, J. T., Pedraza, A., Utsuki, S., Yasui, Y., et al. (2010) · Genes & Development · doi:10.1101/gad.1972310 · Cited by 217
“However, recent technical advances in array-based analysis have allowed increased cytogenetic characterization of complex rearrangements in solid tumors, as exemplified by the identification of the TMPRSS2-ETS fusion in prostate cancer (Tomlins et al. 2005).”
BackgroundIdentification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer
Leyten, G. H. J. M., Hessels, D., Smit, F. P., Jannink, S. A., de Jong, H., Melchers, W. J. G., Cornel, E. B., de Reijke, T. M., Vergunst, H., Kil, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3334 · Cited by 221
Rickman, D. S., Pflueger, D., Moss, B., VanDoren, V. E., Chen, C. X., de la Taille, A., Kuefer, R., Tewari, A. K., Setlur, S. R., Demichelis, F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4926 · Cited by 225
Self-citationHovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Self-citationEndocrine and metabolic aspects of the COVID-19 pandemic
Marazuela, M., Giustina, A., & Puig-Domingo, M. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09569-2 · Cited by 217
“SARS-CoV-2 viral entry requires two host proteins [93]: the angiotensin converting enzyme-2 (ACE2) and the transmembrane protease, serine 2 (TMPRSS2) Androgen receptor activity has been considered a requirement for the transcription of TMPRSS2 gene [94] and TMPRSS2 is the most frequently altered gene in primary prosta…”
BackgroundBiomarkers for Prostate Cancer
Makarov, D. V., Loeb, S., Getzenberg, R. H., & Partin, A. W. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110714 · Cited by 219
ERG gene rearrangements are common in prostatic small cell carcinomas
Lotan, T. L., Gupta, N. S., Wang, W., Toubaji, A., Haffner, M. C., Chaux, A., Hicks, J. L., Meeker, A. K., Bieberich, C. J., De Marzo, A. M., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.7 · Cited by 218
Seminal plasma as a diagnostic fluid for male reproductive system disorders
Drabovich, A. P., Saraon, P., Jarvi, K., & Diamandis, E. P. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.74 · Cited by 209
Ding, Z., Wu, C.-J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A., Chu, G. C., Wang, G., Lu, X., Labrot, E. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.039 · Cited by 220
Gan, W., Dai, X., Lunardi, A., Li, Z., Inuzuka, H., Liu, P., Varmeh, S., Zhang, J., Cheng, L., Sun, Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.026 · Cited by 215
NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma
Kinsey, M., Smith, R., & Lessnick, S. L. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0090 · Cited by 214
Kirby, B. J., Jodari, M., Loftus, M. S., Gakhar, G., Pratt, E. D., Chanel-Vos, C., Gleghorn, J. P., Santana, S. M., Liu, H., Smith, J. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035976 · Cited by 212
MethylSig: a whole genome DNA methylation analysis pipeline
Park, Y., Figueroa, M. E., Rozek, L. S., & Sartor, M. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu339 · Cited by 218
CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
Burkhardt, L., Fuchs, S., Krohn, A., Masser, S., Mader, M., Kluth, M., Bachmann, F., Huland, H., Steuber, T., Graefen, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1342 · Cited by 213
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Galletti, G., Leach, B. I., Lam, L., & Tagawa, S. T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.008 · Cited by 216
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
Parker, B. C., Annala, M. J., Cogdell, D. E., Granberg, K. J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67144 · Cited by 215
Mosquera, J.-M., Perner, S., Genega, E. M., Sanda, M., Hofer, M. D., Mertz, K. D., Paris, P. L., Simko, J., Bismar, T. A., Ayala, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5194 · Cited by 215
Self-citationThe complexity of prostate cancer: genomic alterations and heterogeneity
Boyd, L. K., Mao, X., & Lu, Y.-J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.185 · Cited by 214
Mehra, R., Han, B., Tomlins, S. A., Wang, L., Menon, A., Wasco, M. J., Shen, R., Montie, J. E., Chinnaiyan, A. M., & Shah, R. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2043 · Cited by 214
Self-citationBirnie, R., Bryce, S. D., Roome, C., Dussupt, V., Droop, A., Lang, S. H., Berry, P. A., Hyde, C. F., Lewis, J. L., Stower, M. J., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-5-r83 · Cited by 212
Ding, D., Lou, X., Hua, D., Yu, W., Li, L., Wang, J., Gao, F., Zhao, N., Ren, G., Li, L., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003065 · Cited by 209
Outlier Detection: Applications And Techniques
Singh, K., & Upadhyaya, S. (2012) · Cited by 303
Recurrent chimeric fusion RNAs in non-cancer tissues and cells
Babiceanu, M., Qin, F., Xie, Z., Jia, Y., Lopez, K., Janus, N., Facemire, L., Kumar, S., Pang, Y., Qi, Y., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw032 · Cited by 209
Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer
Cao, Q., Mani, R.-S., Ateeq, B., Dhanasekaran, S. M., Asangani, I. A., Prensner, J. R., Kim, J. H., Brenner, J. C., Jing, X., Cao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.016 · Cited by 204
Self-citationAlekseyenko, A. A., Walsh, E. M., Wang, X., Grayson, A. R., Hsi, P. T., Kharchenko, P. V., Kuroda, M. I., & French, C. A. (2015) · Genes & Development · doi:10.1101/gad.267583.115 · Cited by 198
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Szuhai, K., IJszenga, M., de Jong, D., Karseladze, A., Tanke, H. J., & Hogendoorn, P. C. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2184 · Cited by 204
Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7310 · Cited by 206
Self-citationSOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data
Jia, W., Qiu, K., He, M., Song, P., Zhou, Q., Zhou, F., Yu, Y., Zhu, D., Nickerson, M. L., Wan, S., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-2-r12 · Cited by 204
Mani, K. M., Lefebvre, C., Wang, K., Lim, W. K., Basso, K., Dalla‐Favera, R., & Califano, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.2 · Cited by 205
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer
Soller, M. J., Isaksson, M., Elfving, P., Soller, W., Lundgren, R., & Panagopoulos, I. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20329 · Cited by 195
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 193
Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905931106 · Cited by 203
Evolution of androgen receptor targeted therapy for advanced prostate cancer
Wong, Y. N. S., Ferraldeschi, R., Attard, G., & de Bono, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.72 · Cited by 197
SPOP mutation leads to genomic instability in prostate cancer
Boysen, G., Barbieri, C. E., Prandi, D., Blattner, M., Chae, S.-S., Dahija, A., Nataraj, S., Huang, D., Marotz, C., Xu, L., et al. (2015) · eLife · doi:10.7554/elife.09207 · Cited by 193
Self-citationSantiago, L., Daniels, G., Wang, D., Deng, F., & Lee, P. (2017) · PubMed Central · Cited by 247
Chromosomal translocations induced at specified loci in human stem cells
Brunet, E., Simsek, D., Tomishima, M., DeKelver, R., Choi, V. M., Gregory, P., Urnov, F., Weinstock, D. M., & Jasin, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902076106 · Cited by 200
Harouaka, R., Kang, Z., Zheng, S.-Y., & Cao, L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.004 · Cited by 195
Ren, S., Wei, G.-H., Liu, D., Wang, L., Hou, Y., Zhu, S., Peng, L., Zhang, Q., Cheng, Y., Su, H., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.08.027 · Cited by 199
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
Type II transmembrane serine proteases in development and disease
Szabo, R., & Bugge, T. H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.013 · Cited by 193
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Freeman-Cook, K., Hoffman, R. L., Miller, N., Almaden, J., Chionis, J., Zhang, Q., Eisele, K., Liu, C., Zhang, C., Huser, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.009 · Cited by 189
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing
Pflueger, D., Terry, S., Sboner, A., Habegger, L., Esgueva, R., Lin, P.-C., Svensson, M. A., Kitabayashi, N., Moss, B. J., MacDonald, T. Y., et al. (2011) · Genome Research · doi:10.1101/gr.110684.110 · Cited by 201
Self-citationMarcucci, G., Maharry, K., Whitman, S. P., Vukosavljevic, T., Paschka, P., Langer, C., Mrózek, K., Baldus, C. D., Carroll, A. J., Powell, B. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8720 · Cited by 192
Genomic Predictors of Outcome in Prostate Cancer
Boström, P. J., Bjartell, A. S., Catto, J. W. F., Eggener, S. E., Lilja, H., Loeb, S., Schalken, J., Schlomm, T., & Cooperberg, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.008 · Cited by 187
McBride, D. J., Orpana, A. K., Sotiriou, C., Joensuu, H., Stephens, P. J., Mudie, L. J., Hämäläinen, E., Stebbings, L. A., Andersson, L. C., Flanagan, A. M., et al. (2010) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20815 · Cited by 196
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.